Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group Free PMC article
Full text links

Actions

Share

Review
.2015 Jan;11(1):9-15.
doi: 10.1038/nchembio.1712.

Targeting mitochondria metabolism for cancer therapy

Affiliations
Review

Targeting mitochondria metabolism for cancer therapy

Samuel E Weinberg et al. Nat Chem Biol.2015 Jan.

Abstract

Mitochondria have a well-recognized role in the production of ATP and the intermediates needed for macromolecule biosynthesis, such as nucleotides. Mitochondria also participate in the activation of signaling pathways. Overall, accumulating evidence now suggests that mitochondrial bioenergetics, biosynthesis and signaling are required for tumorigenesis. Thus, emerging studies have begun to demonstrate that mitochondrial metabolism is potentially a fruitful arena for cancer therapy. In this Perspective, we highlight recent developments in targeting mitochondrial metabolism for the treatment of cancer.

PubMed Disclaimer

Conflict of interest statement

Competing financial interests

The authors declare competing financial interests: details accompany the online version of the paper.

Figures

Figure 1
Figure 1. Mitochondria function as bioenergetic, biosynthetic and signaling organelles
Cancer cells catabolize pyruvate and glutamine through the TCA cycle, resulting in the generation of reducing equivalents such as NADH that donate electrons to the ETC. The ETC generates a proton gradient that is used for production of ATP, i.e., oxidative phosphorylation (blue). TCA cycle intermediates can also be directed into biosynthetic pathways (green) that allow for the production of macromolecules (lipids, amino acids and nucleotides). Finally, mitochondrial production of ROS and metabolites act as signaling molecules to alter protein function. Mitochondrial one-carbon metabolism produces NADPH to prevent accumulation of ROS in the mitochondrial matrix. NADPH maintains antioxidant activity of glutathione peroxidase (GPX) and thioredoxin reductases (TrxRs). TA, aminotransferase; VDAC, voltage-dependent anion channel. TRX, thioredoxin; GSH, glutathione; SOD2, superoxide dismutase 2, mitochondrial; 5,10-CH2-THF, 5,10-methylene-tetrahydrofolate.
Figure 2
Figure 2. Targeting mitochondrial bioenergetic capacity
Mitochondrial ATP generation is necessary for tumorigenesis, and few molecules have demonstrated success in preclinical models of cancer. Specifically, (1) the biguanides metformin and phenformin inhibit mitochondrial complex I; (2) VLX600 inhibits the ETC at multiple sites; (3) tigecycline inhibits the mitochondrial ribosomal machinery and consequently the translation of ETC subunits; (4) gamitrinib is an inhibitor of mitochondrial chaperone proteins, such as TRAP-1 and HSP-90. Loss of these chaperones decreases ETC complex stability and subsequently reduces electron transport function. These therapies all share the same ultimate outcome with a decrease in mitochondrial ETC function to reduce mitochondrial bioenergetic capacity. mtDNA, mitochondrial DNA.
Figure 3
Figure 3. Targeting mitochondrial biosynthetic production
Mitochondrial TCA cycle intermediates are siphoned off for utilization as precursors for macromolecule production. Specifically, citrate is transported into the cytosol, where it is converted into acetyl-CoA (a precursor for fatty acid synthesis) and oxaloacetate. Thus, the TCA cycle intermediates have to be replenished for the cycle to continue functioning. Many cancer cells use glutamine, the most abundant amino acid in plasma, to replenish the TCA cycle. Glutaminase converts glutamine to glutamate, which is a precursor for glutathione synthesis. Next, glutamate is converted into the TCA cycle intermediate α-ketoglutarate by GLUD or aminotransferases (TA). The α-ketoglutarate generated from glutamine replenishes the TCA cycle and is also used as a substrate for dioxygenase-dependent reactions. Inhibition of GLS (1) or TA/GLUD (2) have shown efficacy in preclinical models of cancer. (3) Short-term inhibition of autophagy has also shown therapeutic efficacy in preclinical models of cancer. Autophagy generates metabolic substrates for mitochondrial metabolism, particularly glutamine.
Figure 4
Figure 4. Targeting mitochondrial redox signaling and balance
Mitochondrial ETC generates superoxide (O2•−) that can be converted into hydrogen peroxide (H2O2) by SOD2 or traverse through voltage-dependent anion channels (VDACs) into the cytosol. Subsequently, SOD1 converts superoxide into H2O2 to activate redox-dependent signaling. Mitochondrial ROS are necessary for cancer cell proliferation. Thus, mitochondrial-targeted antioxidants are effective in decreasing cancer cell proliferation. Mitochondria prevent accumulation of ROS to levels that would be detrimental to mitochondrial metabolism by increasing antioxidant capacity. NADPH is necessary to maintain the antioxidant function of glutathione peroxidase (GPXs) and thioredoxin reductase (TrxR). Mitochondria maintain redox balance by using SHMT2 and MTHFD2, enzymes in one-carbon metabolism, indicating that this pathway may be a therapeutic target.
Figure 5
Figure 5. Targeting mitochondrial metabolism
Small molecules conjugated to lipophilic cations such as tetraphenylphosphonium (TPP) result in their accumulation in the mitochondrial matrix. Lipophilic conjugated small molecules will first traverse across the plasma membrane and accumulate in the cytosol. This process is driven by the plasma membrane potential (Δψp). Subsequently, the mitochondrial membrane potential (Δψm) will drive the accumulation of these molecules into the mitochondria by several hundredfold.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bonnet S, et al. A mitochondria-K channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11:37–51. - PubMed
    1. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. - PubMed
    1. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA. 1993;90:7915–7922. - PMC - PubMed
    1. Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325–337. - PubMed
    1. Cross CE, et al. Oxygen radicals and human disease. Ann Intern Med. 1987;107:526–545. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp